Excess Iron and Brain Degeneration: The Little-Known LinkMarch 2012
By Kathleen Anderson
Iron accumulation is often a consequence of aging. In the laboratory, total iron content has been shown to increase exponentially as cells age, resulting in 10-fold higher levels of iron compared to young cells.3
Sadly, owing to physician and patient ignorance, the significant dangers posed by excess iron in the body remain little known and often overlooked. As a result, most maturing individuals are not taking aggressive measures to ensure ideal total-body iron status—and most doctors do not properly test for it.
In this article, you will discover the results of a groundbreaking UCLA study published late last year conclusively linking excess iron accumulation in brain tissue to neurodegenerative brain disorders like Alzheimer’s and Parkinson’s.9,10
You will also find a multi-pronged approach to prevent and even reverse iron-induced tissue damage in the brain, liver, and kidneys using nutrients Life Extension® members already take, such as quercetin, curcumin, lipoic acid, and green tea.
Brain Iron Levels, Alzheimer’s Disease, and Cognitive Decline
Dr. George Bartzokis is a widely published researcher and professor of psychiatry at the Semel Institute for Neuroscience and Human Behavior at UCLA. Much of his work has been devoted to understanding the role that iron plays in human brain development, function, and aging, with a particular emphasis on the link between iron and neurodegenerative disorders, including Alzheimer’s and Parkinson’s disease.
From that work, Bartzokis and his colleagues have generated a detailed picture of iron metabolism across the human life span.
Bartzokis’ team showed that they could accurately measure iron levels in living humans’ brains by using a highly specialized non-invasive form of magnetic resonance imaging (MRI).11 Applying this technique to groups of people with and without Alzheimer’s disease, the researchers quickly discovered significantly larger amounts of stored iron in certain brain regions in those with Alzheimer’s than in control subjects.9,12 Similar findings held true in Parkinson’s and Huntington’s disease sufferers as well.10,13
Those discoveries raised the intriguing question of whether the iron was a potential contributor to the neurodegenerative disease process, or whether it was a byproduct of the disease itself.
Further work revealed the definitive answer. First, the brain scan studies showed that increased iron levels were present at the earliest onset of disease, indicating that they were not a consequence but rather a potential cause of brain degeneration.13
Second, even in apparently healthy individuals, iron levels rise steadily with age in some of the very brain regions affected by Alzheimer’s, Parkinson’s, and Huntington’s diseases.14 Those regions include the basal ganglia, which contain the highest levels of iron in the brain.13 Third, the researchers found that people with the highest brain iron accumulations had the earliest age at onset of the degenerative diseases.15
By now it was clear that the presence of excessive iron in affected brain areas was somehow directly involved in triggering the neurodegenerative disease processes. Iron was fast emerging as a potentially modifiable age-related risk factor for these conditions.15
But it wasn’t only neurodegenerative diseases for which excessive iron accumulation was a risk. The UCLA researchers studied a group of healthy older adults, comparing memory and information-processing speed according to their brain iron levels. Those with the highest accumulations of iron in their brain grey matter had the poorest performance, especially among men.16
Bartzokis’ team was struck by several other gender differences apparent in these diseases: men are more likely to develop these conditions at earlier ages than women, and women have significantly lower iron levels in five vital brain regions than men of similar ages.17
A Breakthrough Study
These findings led to a compelling study published in late 2011 demonstrating for the first time that limiting your body’s lifetime exposure to iron can in turn limit your risk of neurodegenerative brain disorders.
It began with the observation that women not only have lower brain iron levels in their later years, they also have lower iron levels throughout their bodies for most of their lives. It has long been known among physicians that this difference arises because women lose iron during their reproductive years through menstruation. Could that steady, low-level loss of iron be an effective means by which women inadvertently but effectively limit their lifetime exposure to iron, thereby protecting themselves from early-onset brain disorders?
Dr. Todd A. Tishler, a protégé of Dr. Bartzokis at UCLA, discovered a way to test that hypothesis. Tishler, Bartzokis, and colleagues studied brain scan images of 39 postmenopausal women, of whom 15 had undergone a hysterectomy prior to menopause.18 Those women obviously had stopped menstruating prior to menopause, prematurely ending their bodies’ ability to lose iron on a regular basis. The other women had experienced regular periods until menopause. For comparison, the researchers included brain scans of 54 men of similar ages.
Not surprisingly, the men’s brains had higher iron levels than those of women who had reached menopause naturally, without hysterectomy. But in a compelling validation of Tishler’s hypothesis, the brains of the women with hysterectomies exhibited iron levels not only higher than normal menopausal women but identical to levels in male subjects.18
The UCLA study demonstrated that lifelong menstruation grants most mature women beneficially lower brain iron levels and affords significant protection against early onset of neurodegenerative brain disorders.
It also underscores the critical need for humans to aggressively limit lifetime exposure to iron and thereby substantially lower their risk of neurodegenerative brain disorders and cognitive decline.
Natural Ways to Limit Iron-Induced Tissue Damage
There are several ways you can limit the damaging effects of excessive iron in your body. The most obvious is to monitor how much iron you ingest. Experts now typically recommend that older adults limit their intake of red meat, which is our major natural dietary source of iron. You should also choose your vitamin and mineral supplements carefully. Unless you have iron-deficiency anemia, you are unlikely to benefit from extra supplemental iron, and it is absent from properly formulated dietary supplements.
But what can you do about the iron your body has already absorbed and has now accumulated in potentially dangerous ways in your tissues? There are two main approaches you should take. The first is to supplement with nutrients that can bind up, or chelate the iron in molecular complexes. Chelation isolates iron from tissues and limits its ability to catalyze the oxidant reactions that damage them. Chelation also hastens excretion of excess iron from your body.19 Ultimately, that means that chelation limits your body’s exposure to the destructive effects of iron accumulations.
The second approach to minimizing long-term iron damage is to optimize your antioxidant regimen. That can help you prevent any further damage by iron’s catalytic reactions with oxygen.
We’ll now examine the compelling data for nutrients that can protect your body from excess iron accumulations by chelating iron, enhancing your antioxidant defenses—or both.
Flavonoids are naturally occurring plant molecules that offer both powerful antioxidant protection and the ability to bind to free iron atoms.19-21 Quercetin, a flavonoid found in berries and other plants, chelates iron atoms as powerfully as the prescription drugs used in managing severe cases of iron overdose.22,23 Quercetin’s antioxidant effects are likely to be closely related to its strong iron-chelating capacity, and account for its ability to prevent the DNA strand damage that precedes cancer development.24,25
Studies of quercetin reveal that it can prevent the kidney damage associated with acute iron overload from muscle breakdown, one of the leading causes of acute renal failure.26 Similarly, liver injury from long-term exposure to iron is prevented in laboratory animals supplemented with quercetin.27,28 Quercetin is included in properly formulated resveratrol supplements since it boosts resveratrol’s beneficial effects in the body.
Cranberry and Pomegranate
Dark-colored and red fruits are known to have many health benefits, in large part because of their high content of polyphenols. Cranberry and pomegranate extracts rich in polyphenols have now been shown to have potent iron-chelating capabilities, in some cases completely suppressing iron-catalyzed oxidant reactions.22,29
We’ve long known that cranberry juice and extracts are active in preventing urinary tract infections with some of the most common pathological organisms. The traditional view has been that the extracts’ antioxidant and anti-adhesive powers are the primary mechanisms.30 New evidence shows that another way cranberry extracts work is by depriving infecting bacteria of the iron they need for survival through chelation.30,31
Green Tea Extract
After water, tea is the most commonly-consumed beverage in the world.32 Green, unfermented tea leaves have numerous health benefits, chiefly attributable to their content of a polyphenol molecule called epigallocatechin-3-gallate, or EGCG.32 EGCG is a well-known antioxidant.33 In recent years, it was shown to powerfully chelate unbound iron and protect vulnerable tissues.34,35
Green tea extracts rich in EGCG bind to iron, and scientists have proposed their use as an alternative or adjunct to commercial iron chelators, which, while effective, may come with negative side effects.36,37 Such drugs are used to treat thalassemia, a condition which when severe enough, can cause massive iron accumulations as the result of frequent blood transfusions. EGCG from green tea has now been used safely and effectively to bind and remove iron from the blood of individuals with thalassemia.37,38 And in studies of animals deliberately overloaded with iron to mimic aging, green tea extracts are able to bind free iron and reduce iron-related tissue oxidation in brain and liver tissue.36,39,40
Unlike many drugs and nutrients, EGCG readily crosses the blood-brain barrier.41,42 This allows it to capture and isolate iron from the brain regions affected in Alzheimer’s, Parkinson’s, and Huntington’s diseases.43 In contrast to many current drug therapies, which can only modify symptoms in these tragic conditions, iron chelation by EGCG rich green tea extract offers the potential to prevent and reverse the progression of the disease process itself.44-46
Curcumin is the major chemical component of the spice turmeric, which has multiple health benefits as an antioxidant and anti-inflammatory molecule.47-49 The unexpected discovery that curcumin is also a powerful iron chelator has given us new insight into its multimodal mechanisms of action in gaining control of age-related iron accumulations in the brain, heart, and liver.50-53
Iron chelation by curcumin is now recognized as one of the mechanisms by which it prevents cognitive deficits and pathological tissue changes in animal models of Alzheimer’s disease.48 In addition to its direct chelation of iron, curcumin induces increased genetic expression of the body’s natural iron-binding and transport protein, ferritin, further sequestering iron away from vulnerable tissues.50 These multiple capabilities lead directly to reduction in iron levels in iron-overloaded organs.50,53-55
Recently, it was discovered that curcumin’s iron-chelating ability helps restore natural DNA repair mechanisms, an additional means of protecting damaged neurons in Alzheimer’s and Parkinson’s diseases.56 And, in a fashion similar to cranberry polyphenols, curcumin can inhibit growth of microorganisms (in this case, yeast) by depriving them of the iron they need to reproduce.57
Milk Thistle (Silymarin and Silibinin)
Milk thistle extracts have been used for centuries in managing diseases of the liver and gallbladder.58 Iron accumulations and the resulting oxidant stress in liver tissue are responsible for progressive fibrosis (scarring) and ultimately liver failure.2,59 Early work on milk thistle extracts focused on their antioxidant functions, but more recently evidence for potent iron chelation has been revealed as an additional liver-protective mechanism.58,60 Iron-overloaded animals can be protected from the liver fibrosis-inducing effects of iron by regular doses of silibinin, a milk thistle component.2,59
Impressive human data for the impact of silibinin on iron-overloaded patients is now available. In patients with chronic hepatitis C, in whom iron accumulations contribute to liver failure, treatment with a mixture of silibinin and soy complex resulted in a significant decrease in serum levels of ferritin, the iron-bound protein that reflects total body iron levels.61 In patients with thalassemia major, who have massive iron accumulations as a result of multiple transfusions, 140 mg three times per day of the milk thistle component silymarin enhanced the iron-chelating effects of the drug desferrioxamine.62 Similar results have been shown using 140 mg per day of silibinin in patients with another form of iron overload, hereditary hemochromatosis.63
Lipoic Acid and Carnitine
Lipoic acid and carnitine are small-molecule nutrients vital to your body’s management of its energy flow.64,65 Potent antioxidants, they are both credited with protecting mitochondria and thereby slowing the aging process. Exciting work is now emerging that shows that each of these nutrients, in each of several forms, exerts its favorable anti-aging effects by chelating iron as well.64-66
A form of carnitine called L-propionyl carnitine is known to improve heart muscle recovery after a heart attack. It acts as an energy source for heart muscles, and also as an anti-free radical agent in damaged heart tissue; the latter effect has now been shown to be the result of iron chelation.65 Another form, acetyl-L-carnitine, exhibits powerful antioxidant effects that reverse the impact of iron-induced oxidative stress in human cells.67
Lipoic acid chelates iron in lysosomes, cellular components that are a site of iron storage, effectively preventing iron-induced oxidative damage.68,69 This nutrient also reduces iron uptake by cells in the lens of the eye, suggesting a potential role in preventing cataract formation.70
An important animal study has now demonstrated that supplementation with R-lipoic acid reverses age-related accumulation of iron in rat brain tissue and restores normal antioxidant activity.71 This study has direct bearing on the prevention and treatment of neurodegenerative diseases in humans, the very conditions that Dr. Bartzokis and colleagues have been studying at UCLA.
Accumulation of iron in cells is a widely overlooked and inevitable consequence of aging. Pathologic age-related iron overload damages cells and tissues and is a causative factor in numerous degenerative diseases, including liver fibrosis, cardiovascular disease, and cancer. Few doctors inform their patients of the dangers of excess iron, nor do they test for total-body iron status. Excessive iron accumulations are found in affected brain areas of people with Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. Even in normal older adults, people with higher brain iron accumulations perform more poorly on cognitive tests than do those with lower brain iron concentrations. A breakthrough UCLA study demonstrates that limiting lifetime exposure to iron can reduce brain iron accumulation. A number of nutrients can help reduce your body’s total exposure to iron through chelation (binding to free iron atoms) and antioxidant activity. These include quercetin, curcumin, R-lipoic acid, and milk thistle.
The majority of people should avoid multi-vitamin supplements fortified with iron, as most aging individuals already have too much iron in their bodies. •
If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.
1. Tuomainen TP, Loft S, Nyyssönen K, Punnonen K, Salonen JT, Poulsen HE. Body iron is a contributor to oxidative damage of DNA. Free Radic Res. 2007 Mar;41(3):324-8.
2. Masini A, Ceccarelli D, Giovannini F, Montosi G, Garuti C, Pietrangelo A. Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils. The effect of silybin. J Bioenerg Biomembr. 2000 Apr;32(2):175-82.
3. Killilea DW, Atamna H, Liao C, Ames BN. Iron accumulation during cellular senescence in human fibroblasts in vitro. Antioxid Redox Signal. 2003 Oct;5(5):507-16.
4. Xu J, Knutson MD, Carter CS, Leeuwenburgh C. Iron accumulation with age, oxidative stress and functional decline. PLoS One. 2008;3(8):e2865.
5. Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer’s disease, Parkinson’s disease and atherosclerosis. J Alzheimers Dis. 2009;16(4):879-95.
6. Ong WY, Jenner AM, Pan N, Ong CN, Halliwell B. Elevated oxidative stress, iron accumulation around microvessels and increased 4-hydroxynonenal immunostaining in zone 1 of the liver acinus in hypercholesterolemic rabbits. Free Radic Res. 2009 Mar;43(3):241-9.
7. Klipstein-Grobusch K, Koster JF, Grobbee DE, et al. Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr. 1999 Jun;69(6):1231-6.
8. Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer. 1994 Feb 1;56(3):364-9.
9. Bartzokis G, Sultzer D, Cummings J, et al. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry. 2000 Jan;57(1):47-53.
10. Bartzokis G, Cummings JL, Markham CH, et al. MRI evaluation of brain iron in earlier- and later-onset Parkinson’s disease and normal subjects. Magn Reson Imaging. 1999 Feb;17(2):213-22.
11. Bartzokis G, Mintz J, Sultzer D, et al. In vivo MR evaluation of age-related increases in brain iron. AJNR Am J Neuroradiol. 1994 Jun;15(6):1129-38.
12. Bartzokis G, Sultzer D, Mintz J, et al. In vivo evaluation of brain iron in Alzheimer’s disease and normal subjects using MRI. Biol Psychiatry. 1994 Apr 1;35(7):480-7.
13. Bartzokis G, Tishler TA. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer’s and Huntingon’s disease. Cell Mol Biol (Noisy-le-grand). 2000 Jun;46(4):821-33.
14. Bartzokis G, Beckson M, Hance DB, Marx P, Foster JA, Marder SR. MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn Reson Imaging. 1997;15(1):29-35.
15. Bartzokis G, Tishler TA, Shin IS, Lu PH, Cummings JL. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann N Y Acad Sci. 2004 Mar;1012:224-36.
16. Bartzokis G, Lu PH, Tingus K, et al. Gender and iron genes may modify associations between brain iron and memory in healthy aging. Neuropsychopharmacology. 2011 Jun;36(7):1375-84.
17. Bartzokis G, Tishler TA, Lu PH, et al. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging. 2007 Mar;28(3):414-23.
18. Tishler TA, Raven EP, Lu PH, Altshuler LL, Bartzokis G. Premenopausal hysterectomy is associated with increased brain ferritin iron. Neurobiol Aging. 2011 Sep 16.
19. Vlachodimitropoulou E, Sharp PA, Naftalin RJ. Quercetin-iron chelates are transported via glucose transporters. Free Radic Biol Med. 2011 Apr 15;50(8):934-44.
20. Morel I, Lescoat G, Cogrel P, et al. Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and diosmetin on iron-loaded rat hepatocyte cultures. Biochem Pharmacol. 1993 Jan 7;45(1):13-9.
21. Ferrali M, Signorini C, Caciotti B, et al. Protection against oxidative damage of erythrocyte membrane by the flavonoid quercetin and its relation to iron chelating activity. FEBS Lett. 1997 Oct 20;416(2):123-9.
22. Guo M, Perez C, Wei Y, et al. Iron-binding properties of plant phenolics and cranberry’s bio-effects. Dalton Trans. 2007 Nov 21 (43):4951-61.
23. Mladenka P, Macakova K, Filipsky T, et al. In vitro analysis of iron chelating activity of flavonoids. J Inorg Biochem. 2011 May;105(5):693-701.
24. Sestili P, Guidarelli A, Dacha M, Cantoni O. Quercetin prevents DNA single strand breakage and cytotoxicity caused by tert-butylhydroperoxide: free radical scavenging versus iron chelating mechanism. Free Radic Biol Med. 1998 Jul 15;25(2):196-200.
25. Cheng IF, Breen K. On the ability of four flavonoids, baicilein, luteolin, naringenin, and quercetin, to suppress the Fenton reaction of the iron-ATP complex. Biometals. 2000 Mar;13(1):77-83.
26. Chander V, Singh D, Chopra K. Reversal of experimental myoglobinuric acute renal failure in rats by quercetin, a bioflavonoid. Pharmacology. 2005 Jan;73(1):49-56.
27. Zhang Y, Li H, Zhao Y, Gao Z. Dietary supplementation of baicalin and quercetin attenuates iron overload induced mouse liver injury. Eur J Pharmacol. 2006 Mar 27;535(1-3):263-9.
28. Zhang Y, Gao Z, Liu J, Xu Z. Protective effects of baicalin and quercetin on an iron-overloaded mouse: comparison of liver, kidney and heart tissues. Nat Prod Res. 2011 Jul;25(12):1150-60.
29. Kulkarni AP, Mahal HS, Kapoor S, Aradhya SM. In vitro studies on the binding, antioxidant, and cytotoxic actions of punicalagin. J Agric Food Chem. 2007 Feb 21;55(4):1491-500.
30. Lin B, Johnson BJ, Rubin RA, Malanoski AP, Ligler FS. Iron chelation by cranberry juice and its impact on Escherichia coli growth. Biofactors. 2011 Mar;37(2):121-30.
31. Hidalgo G, Ponton A, Fatisson J, et al. Induction of a state of iron limitation in uropathogenic Escherichia coli CFT073 by cranberry-derived proanthocyanidins as revealed by microarray analysis. Appl Environ Microbiol. 2011 Feb;77(4):1532-5.
32. Weinreb O, Amit T, Mandel S, Youdim MB. Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr. 2009 Sep 10.
33. Weinreb O, Mandel S, Amit T, Youdim MB. Neurological mechanisms of green tea polyphenols in Alzheimer’s and Parkinson’s diseases. J Nutr Biochem. 2004 Sep;15(9):506-16.
34. Grinberg LN, Newmark H, Kitrossky N, Rahamim E, Chevion M, Rachmilewitz EA. Protective effects of tea polyphenols against oxidative damage to red blood cells. Biochem Pharmacol. 1997 Nov 1;54(9):973-8.
35. Mandel SA, Avramovich-Tirosh Y, Reznichenko L, et al. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals. 2005;14(1-2):46-60.
36. Saewong T, Ounjaijean S, Mundee Y, et al. Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice. Med Chem. 2010 Mar;6(2):57-64.
37. Srichairatanakool S, Ounjaijean S, Thephinlap C, Khansuwan U, Phisalpong C, Fucharoen S. Iron-chelating and free-radical scavenging activities of microwave-processed green tea in iron overload. Hemoglobin. 2006;30(2):311-27.
38. Thephinlap C, Ounjaijean S, Khansuwan U, Fucharoen S, Porter JB, Srichairatanakool S. Epigallocatechin-3-gallate and epicatechin-3-gallate from green tea decrease plasma non-transferrin bound iron and erythrocyte oxidative stress. Med Chem. 2007 May;3(3):289-96.
39. Ounjaijean S, Thephinlap C, Khansuwan U, et al. Effect of green tea on iron status and oxidative stress in iron-loaded rats. Med Chem. 2008 Jul;4(4):365-70.
40. Reznichenko L, Amit T, Zheng H, et al. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer’s disease. J Neurochem. 2006 Apr;97(2): 527-36.
41. Mandel S, Amit T, Reznichenko L, Weinreb O, Youdim MB. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Mol Nutr Food Res. 2006 Feb;50(2):229-34.
42. Mandel S, Weinreb O, Reznichenko L, Kalfon L, Amit T. Green tea catechins as brain-permeable, non toxic iron chelators to “iron out iron” from the brain. J Neural Transm Suppl. 2006 (71):249-57.
43. Mandel S, Maor G, Youdim MB. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J Mol Neurosci. 2004;24(3):401-16.
44. Mandel S, Amit T, Bar-Am O, Youdim MB. Iron dysregulation in Alzheimer’s disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog Neurobiol. 2007 Aug;82(6):348-60.
45. Weinreb O, Amit T, Youdim MB. A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate. Free Radic Biol Med. 2007 Aug 15;43(4):546-56.
46. Mandel SA, Amit T, Kalfon L, Reznichenko L, Weinreb O, Youdim MB. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). J Alzheimers Dis. 2008 Oct;15(2):211-22.
47. Sreejayan, Rao MN. Curcuminoids as potent inhibitors of lipid peroxidation. J Pharm Pharmacol. 1994 Dec;46(12):1013-6.
48. Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer’s disease animal models. J Alzheimers Dis. 2004 Aug;6(4):367-77; discussion 443-9.
49. Wang J, Du XX, Jiang H, Xie JX. Curcumin attenuates 6-hydroxydopamine-induced cytotoxicity by anti-oxidation and nuclear factor-kappa B modulation in MES23.5 cells. Biochem Pharmacol. 2009 Jul 15;78(2):178-83.
50. Jiao Y, Wilkinson J 4th, Christine Pietsch E, et al. Iron chelation in the biological activity of curcumin. Free Radic Biol Med. 2006 Apr 1;40(7):1152-60.
51. Dairam A, Fogel R, Daya S, Limson JL. Antioxidant and iron-binding properties of curcumin, capsaicin, and S-allylcysteine reduce oxidative stress in rat brain homogenate. J Agric Food Chem. 2008 May 14;56(9):3350-6.
52. Jiao Y, Wilkinson Jt, Di X, et al. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood. 2009 Jan 8;113(2):462-9.
53. Thephinlap C, Phisalaphong C, Lailerd N, et al. Reversal of cardiac iron loading and dysfunction in thalassemic mice by curcuminoids. Med Chem. 2011 Jan;7(1):62-9.
54. Srichairatanakool S, Thephinlap C, Phisalaphong C, Porter JB, Fucharoen S. Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma. Med Chem. 2007 Sep;3(5):469-74.
55. Thephinlap C, Phisalaphong C, Fucharoen S, Porter JB, Srichairatanakool S. Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice. Med Chem. 2009 Sep;5(5):474-82.
56. Hegde ML, Hegde PM, Holthauzen LM, Hazra TK, Rao KS, Mitra S. Specific inhibition of NEIL-initiated repair of oxidized base damage in human genome by copper and iron: potential etiological linkage to neurodegenerative diseases. J Biol Chem. 2010 Sep 10;285(37):28812-25.
57. Minear S, O’Donnell AF, Ballew A, et al. Curcumin inhibits growth of Saccharomyces cerevisiae through iron chelation. Eukaryot Cell. 2011 Sep 9.
58. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998 Feb;93(2):139-43.
59. Pietrangelo A, Montosi G, Garuti C, et al. Iron-induced oxidant stress in nonparenchymal liver cells: mitochondrial derangement and fibrosis in acutely iron-dosed gerbils and its prevention by silybin. J Bioenerg Biomembr. 2002 Feb;34(1):67-79.
60. Borsari M, Gabbi C, Ghelfi F, et al. Silybin, a new iron-chelating agent. J Inorg Biochem. 2001 Jun;85(2-3):123-9.
61. Bares JM, Berger J, Nelson JE, et al. Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C. J Clin Gastroenterol. 2008 Sep;42(8):937-44.
62. Gharagozloo M, Moayedi B, Zakerinia M, et al. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial. Fundam Clin Pharmacol. 2009 Jun;23(3):359-65.
63. Hutchinson C, Bomford A, Geissler CA. The iron-chelating potential of silybin in patients with hereditary haemochromatosis. Eur J Clin Nutr. 2010 Oct;64(10):1239-41.
64. Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem. 2004 May;11(9):1135-46.
65. Suh JH, Zhu BZ, deSzoeke E, Frei B, Hagen TM. Dihydrolipoic acid lowers the redox activity of transition metal ions but does not remove them from the active site of enzymes. Redox Rep. 2004;9(1):57-61.
66. Reznick AZ, Kagan VE, Ramsey R, et al. Antiradical effects in L-propionyl carnitine protection of the heart against ischemia-reperfusion injury: the possible role of iron chelation. Arch Biochem Biophys. 1992 Aug 1;296(2):394-401.
67. Lal A, Atamna W, Killilea DW, Suh JH, Ames BN. Lipoic acid and acetyl-carnitine reverse iron-induced oxidative stress in human fibroblasts. Redox Rep. 2008;13(1):2-10.
68. Persson HL, Svensson AI, Brunk UT. Alpha-lipoic acid and alpha-lipoamide prevent oxidant-induced lysosomal rupture and apoptosis. Redox Rep. 2001;6(5):327-34.
69. Persson HL, Yu Z, Tirosh O, Eaton JW, Brunk UT. Prevention of oxidant-induced cell death by lysosomotropic iron chelators. Free Radic Biol Med. 2003 May 15;34(10):1295-305.
70. Goralska M, Dackor R, Holley B, McGahan MC. Alpha lipoic acid changes iron uptake and storage in lens epithelial cells. Exp Eye Res. 2003 Feb;76(2):241-8.
71. Suh JH, Moreau R, Heath SH, Hagen TM. Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep. 2005;10(1):52-60.
72. Sebastiani G, Pantopoulos K. Disorders associated with systemic or local iron overload: from pathophysiology to clinical practice. Metallomics. 2011 Oct 4;3(10):971-86.
73. Xu J, Marzetti E, Seo AY, Kim JS, Prolla TA, Leeuwenburgh C. The emerging role of iron dyshomeostasis in the mitochondrial decay of aging. Mech Ageing Dev. 2010 Jul-Aug;131(7-8):487-93.